Clarity Pharmaceuticals (ASX:CU6): How SAR Technology Supports Its Cancer Imaging and Therapy Programs

Aditi Sarkar

14 October 2026 08:15 PM AEDT

Clarity Pharmaceuticals (ASX:CU6): How SAR Technology Supports Its Cancer Imaging and Therapy Programs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clarity is developing copper-based radiopharmaceuticals for cancer imaging and treatment.
Its SAR chelator is designed to retain radioactive copper within targeted molecules.
The SECuRE trial reached its main cohort expansion recruitment target in October 2026.
An August 2026 clinical update reported prostate-specific antigen responses in evaluable participants.
Clinical development and regulatory review remain necessary before any investigational product can be marketed.

Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage radiopharmaceutical company developing targeted copper-based products for the diagnosis and treatment of cancer. Its research centres on a sarcophagine, or SAR, chelator that binds copper radioisotopes to cancer-targeting molecules. During 2026, the company reported progress in the SECuRE prostate cancer trial, providing a current clinical setting in which the platform is being evaluated.

How the SAR Copper Cage Works

The chelator is a component of a radiopharmaceutical: it holds a radioactive metal while a linked targeting molecule directs the agent towards particular biological structures. Clarity Pharmaceuticals (ASX:CU6) describes its SAR cage as a way to limit the release of copper isotopes after administration. This property matters because unwanted isotope distribution can affect image interpretation and tissue exposure. However, chemical retention alone does not establish clinical benefit or regulatory approval.

Clarity uses copper-64 for positron emission tomography (PET) imaging and copper-67 in investigational targeted radiation treatment. Its product candidates pair these isotopes with molecules designed to bind cancer-associated targets. The combination of diagnosis and therapy is commonly described as theranostics, although the specific uses of each candidate are being evaluated separately.

SECuRE Trial Reaches an October 2026 Milestone

On 8 October 2026, Clarity Pharmaceuticals (ASX:CU6) announced that the main group of the SECuRE Phase I/IIa cohort expansion had reached its recruitment target of 16 participants with metastatic castration-resistant prostate cancer. These participants are being assessed after treatment with up to six cycles of 8 GBq of copper-67 SAR-bisPSMA. Recruitment continued for an additional group evaluating the agent alongside enzalutamide.

The company also reported findings from 19 participants in an August 2026 data update. Among evaluable participants at the 8 GBq dose level, 74% achieved a prostate-specific antigen reduction of at least 25%, while 63% achieved a reduction of at least 50%. Among 16 participants evaluable by imaging, 81% had disease control under the measures described by the company. These interim findings concern a limited study population and are not results from a completed registration trial.

Diagnostic Development Beyond Treatment

Clarity Pharmaceuticals (ASX:CU6) is also developing copper-64 SAR-bisPSMA imaging in prostate cancer, including its CLARIFY and AMPLIFY programs. Its other named programs include SARTATE for neuroendocrine tumour imaging and SAR-Bombesin for selected prostate cancer imaging settings. The candidates involve different targets and clinical questions, so evidence from one trial cannot automatically be applied to another.

A key technical consideration in PET imaging is background activity in tissues such as the liver. The company says the SAR cage is designed to hold copper securely and support clearer assessment of targeted lesions. Whether these characteristics translate into adequate diagnostic performance depends on results from each clinical program and assessment by relevant regulators.

Clinical, Manufacturing and Funding Considerations

Clarity Pharmaceuticals (ASX:CU6) remains exposed to clinical trial outcomes, safety evaluation, trial recruitment, manufacturing consistency and regulatory decisions. Larger studies may produce different findings from early-stage observations. The company also needs sufficient funding to complete development work; no cash-runway estimate is included here because the supplied material does not substantiate one.

Key Insights

The 2026 SECuRE recruitment milestone shows that Clarity Pharmaceuticals (ASX:CU6) has progressed evaluation of copper-67 SAR-bisPSMA in a defined prostate cancer population. Its SAR chelator is an enabling technology across several imaging and treatment candidates, but clinical results and regulatory assessments determine each product’s eventual status. The distinction between preliminary observations and completed trial evidence remains central to understanding the pipeline.

FAQs

Q: What does Clarity Pharmaceuticals develop?

A:It develops investigational copper-based radiopharmaceutical products for cancer imaging and treatment.

Q: What is SAR technology?

A:It is a sarcophagine chelator system intended to retain copper isotopes within targeted radiopharmaceutical compounds.

Q: What was announced in October 2026?

A:The SECuRE trial reached its recruitment target of 16 participants in the main cohort expansion group.

Q: Are SECuRE findings final?

A:No. The reported results are interim clinical findings from participants assessed to date.

Q: Is copper-64 used for the same purpose as copper-67?

A:Copper-64 is used in the company’s PET imaging candidates, while copper-67 is being evaluated in treatment candidates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.